CCO Treatment Updates

Understanding the Optimal Use and Interpretation of Assays in HCV

Interactive Virtual Presentation

Understanding the Optimal Use and Interpretation of Assays in HCV

Faculty: Paul Y. Kwo, MD CREDIT INFORMATION Release Date: 12/2/11 Expiration Date: 12/1/12 Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Status: Please log in to view status

In this Interactive Virtual Presentation, Paul Y. Kwo, MD, provides practical recommendations regarding the use of the various HCV assays available to guide the management of patients considering or already receiving treatment. Learning Objectives Upon completion of this activity, participants should be able to: Implement the appropriate HCV RNA assay(s) to monitor response during therapy with a protease inhibitor plus peginterferon/ribavirin Employ the appropriate HCV RNA cutoff values to determine eligibility for response-guided therapy and sustained virologic response in patients receiving a protease inhibitor plus peginterferon/ribavirin Critically appraise the information gleaned from other HCV-related assays including IL28B genotype and viral genotype/subgenotype Apply current guideline recommendations on the use of HCV-related assays before and during HCV therapy

Slideset: Understanding the Optimal Use and Interpretation of Assays in HCV

tology&source=twitter